Treatment Pattern Analysis and Health-care Resource Consumption on Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Biological Drugs in a Northern Italian Region

Figures & data

Table 1 Baseline Characteristics of PSA Patients Stratified for Biological Treatments

Biologics	Patients N (%)	Age ±SD	Male (%)	Co-diagnosis
				RA	CD/UC	PSO
Adalimumab	749 (40.3)	51.3 ± 12.0	378 (50.5)	119 (15.9)	28 (3.7)	342 (45.7)
Certolizumab	55 (3.0)	51.7 ± 11.2	24 (43.6)	17 (30.9)	0 (0.0)	16 (29.1)
Etanercept	661 (35.6)	54.7 ± 12.0	360 (54.5)	145 (21.9)	NI	362 (54.8)
Golimumab	149 (8.0)	50.9 ± 9.9	76 (51.0)	17 (11.4)	NI	65 (43.6)
Infliximab	139 (7.5)	51.9 ± 10.0	95 (68.3)	19 (13.7)	24 (17.3)	73 (52.5)
Ustekinumab	104 (5.6)	53.1 ± 11.2	64 (61.5)	8 (7.7)	NI	89 (85.6)

Notes: Following the “Opinion 05/2014 on Anonymization Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving fewer than three patients were reported “not issuable”, as potentially reconductable to single individuals.

Abbreviations: RA, rheumatoid arthritis; CD/UC, Crohn’s disease/ulcerative colitis; PSO, psoriasis; NI, not issuable.

Table 2 Baseline Characteristics of as Patients Stratified for Biological Treatments

Biologics	Patients N (%)	Age ±SD	Male (%)	Co-diagnosis
				RA	CD/UC	PSO
Adalimumab	339 (45.5)	44.9 ± 13.1	196 (57.8)	41 (12.1)	55 (16.2)	0 (0.0)
Certolizumab	11 (1.5)	49.7 ± 8.7	8 (72.7)	NI	NI	0 (0.0)
Etanercept	194 (26)	46.8 ± 14.0	123 (63.4)	33 (17.0)	6 (3.1)	0 (0.0)
Golimumab	72 (9.7)	48.5 ± 12.1	45 (62.5)	8 (11.1)	4 (5.6)	0 (0.0)
Infliximab	129 (17.3)	48.4 ± 13.5	91 (70.5)	20 (15.5)	46 (35.7)	0 (0.0)

Notes: Following the “Opinion 05/2014 on Anonymization Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving fewer than three patients were reported “not issuable”, as potentially reconductable to single individuals.

Abbreviations: RA, rheumatoid arthritis; CD/UC, Crohn’s disease/ulcerative colitis; PSO, psoriasis; NI, not issuable.

Figure 1 Flowchart of included patients.

Figure 2 Concomitant treatment with csDMARDs in PSA (A) and AS (B) cohorts.

Abbreviations: Adal, adalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 3 Patient treated with more than one biological (switches) in PSA (A) and AS (B) cohorts.

Abbreviations: Adal, adalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 4 Adherence and persistence to treatment in the PSA (A) and AS (B) cohorts.

Abbreviations: Adal, adalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 5 Biological treatment interruptions in PSA (A) and AS (B) cohorts.

Abbreviations: Adal, aalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 6 Patients with an hospitalization related to PSA in PSA cohort (A) and AS in AS cohort (B).

Abbreviations: Adal, adalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 7 Percentage of patients with a specialist visit/laboratory test related to PSA in PSA cohort (A) and AS in AS cohort (B).

Abbreviations: Adal, adalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 8 Mean number of specialist visit/laboratory test related to PSA in PSA cohort (A) and AS in AS cohort (B).

Abbreviations: Adal, adalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 9 Annual cost per patient affected by PSA.

Abbreviations: PSA, psoriatic arthritis; csDMARD, conventional synthetic disease-modifying drug; Adal, adalimumab; Cert, certolizumab; Etan, etanercept; Goli, golimumab; Infl, infliximab; Ustek, ustekinumab.

Figure 10 Annual cost per patient affected by PSA.

Abbreviations: AS, ankylosing spondylitis; csDMARD, conventional synthetic disease-modifying drug; Adal, aalimumab; Cert, certolizumab; Etan, eanercept; Goli, golimumab; Infl, infliximab.